Effect of Treatment on Bone Mineral Density
Conditions
Brief summary
To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.
Detailed description
This study is a phase III single-blind placebo-controlled safety study with a 52 week active dosing period with Androxal. Safety will be assessed by physical and visual acuity exams, slit lamp and fundoscopy eye exams, clinical laboratory tests, DEXA scanning, lean soft tissue assessment (LST), and adverse event reporting. Results will be compared to an age-matched placebo group.
Interventions
12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
DRUGPlacebo
1 placebo capsule per day, oral
Sponsors
Repros Therapeutics Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Overweight (BMI 25 to 42 kg/m2 inclusive, or BMI 23 to 42 inclusive in Asian subjects) males age 18 to 60 inclusive 2. Men currently using topical testosterone products should wash-out for at least 7 days before Visit 1 3. All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor) 4. Previously or concurrently diagnosed as having secondary hypogonadism and confirmed with morning testosterone \<300ng/dL measured twice on separate days. One of the two TT levels must be confirmed at baseline. Subjects who fail this criterion will be enrolled in the placebo group. 5. LH \<9.4 mIU/mL (at Visit 1 only) 6. Ability to complete the study in compliance with the protocol 7. Ability to understand and provide written informed consent
Exclusion criteria
1. Use of an injectable or pelleted testosterone within 6 months prior to study (men currently on topical products may be enrolled in the study after a 7-day washout period) 2. Use of testosterone injection, spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study 3. Use of Clomid in the past year 4. Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics need to be treated for at least 48 hours before being enrolled in the study 5. Clinically significant abnormal findings at screening (Visit 1), based on the Investigator's assessment. 6. A hematocrit \>54% or a hemoglobin \>17 g/dL 7. Clinically significant abnormal laboratory findings at baseline (Visit 2), based on the Investigator's assessment 8. Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication. 9. Known hypersensitivity to Clomid 10. Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade \> 2 based on 0-4 scale or any trace of posterior subcapsular cataract) 11. Abnormal fundoscopy exam such as central retinal vein occlusion 12. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study 13. Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, or tumors of the pituitary) 14. Current or history of breast cancer 15. Subjects with a Z-score of \<2 16. Hyperparathyroidism, metabolic bone disease, previous fracture of the spine, recent chemotherapy, use of medications that may influence BMD (thyroid replacement therapy, immunosuppressive therapy, prednisone or antiepileptic drugs 17. No intravenous or oral contrast agents within 7 days. 18. Subject weighs \>300 pounds (\>136 kg) 19. Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA\>3.6 20. Presence or history of known hyperprolactinemia with or without a tumor 21. Chronic use of medications use such as glucocorticoids 22. History of drug abuse or chronic narcotic use including methadone 23. Subjects with known history of HIV and/or Hepatitis C 24. Subjects with end stage renal disease 25. Subjects with cystic fibrosis (mutation of the CFTR gene) 26. Enrollment in a previous Androxal study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bone Mineral Density | 52 weeks | Change in bome mineral density at the end of study compared to placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Testosterone | 52 weeks | Changes of values from baseline in total morning Testosterone levels at week 52. |
Countries
United States
Outcome results
None listed